Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ronan Flippot, Ziad Bakouny, Xiao X. Wei, David A. Braun, Bradley Alexander McGregor, John A. Steinharter, Lauren Christine Harshman, Ulka N. Vaishampayan, Mariano Severgnini, David F. McDermott, F. Stephen Hodi, Gwo-Shu Mary Lee, Eliezer Mendel Van Allen, Sabina Signoretti, Toni K. Choueiri, Rana R. McKay
Institutions: Dana-Farber Cancer Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center, University of California San Diego, Moores Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3007270195